BioLife Solutions (BLFS) Projected to Post Earnings on Thursday

Key Points

• BioLife Solutions is set to announce its Q2 2025 earnings on August 7th, with expectations of a loss of ($0.02) per share and revenues of $23.71 million.
• Following a recent transaction, major shareholder Casdin Partners sold 1 million shares of BioLife Solutions for approximately $23.8 million, reducing their stake by 11.48%.
• Multiple analysts have differing views on the stock, with one rating it a "sell" while others maintain "buy" ratings and a consensus target price of $31.00.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect BioLife Solutions to post earnings of ($0.02) per share and revenue of $23.71 million for the quarter. BioLife Solutions has set its FY 2025 guidance at EPS.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. The company had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Performance

BLFS traded up $0.36 on Monday, reaching $21.17. The company had a trading volume of 105,877 shares, compared to its average volume of 463,859. The company has a quick ratio of 3.74, a current ratio of 4.73 and a debt-to-equity ratio of 0.01. BioLife Solutions has a 1 year low of $19.10 and a 1 year high of $29.55. The stock has a market capitalization of $1.01 billion, a PE ratio of -72.93 and a beta of 1.76. The stock has a 50-day moving average price of $22.00 and a 200-day moving average price of $23.76.

Insider Buying and Selling at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total transaction of $23,800,000.00. Following the transaction, the insider directly owned 7,707,165 shares in the company, valued at $183,430,527. The trade was a 11.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 1,008,831 shares of company stock worth $23,999,658 over the last three months. 2.20% of the stock is owned by company insiders.

Institutional Trading of BioLife Solutions

Several hedge funds have recently modified their holdings of BLFS. Jacobs Levy Equity Management Inc. purchased a new position in BioLife Solutions in the 1st quarter valued at approximately $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in BioLife Solutions by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider's stock valued at $489,000 after acquiring an additional 914 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of BioLife Solutions in the first quarter valued at approximately $1,091,000. Finally, Strs Ohio purchased a new position in shares of BioLife Solutions during the 1st quarter worth approximately $153,000. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Finally, Stephens began coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, BioLife Solutions currently has an average rating of "Moderate Buy" and an average target price of $31.00.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.